论文部分内容阅读
[目的]探讨替吉奥同期调强放疗对高龄晚期食管鳞癌患者的近期疗效和安全性。[方法 ]高龄晚期食管鳞癌患者100例,随机分为两组,每组50例,所有患者均采用全程调强适形放射治疗(IMRT),治疗组在此基础上同时于放疗第1 d开始口服替吉奥胶囊治疗,化疗3个周期后观察两组患者近期疗效,同时记录患者的1年生存率、局部控制率及生存时间以及不良反应发生率。[结果]两组患者治疗后,治疗组的近期有效率达84.00%,对照组的近期有效率仅为62.00%,治疗组的近期疗效优于对照组,差异有统计学意义(P<0.05);两组患者治疗后,治疗组的1年生存率、局部控制率、平均生存时间均明显高于对照组(P<0.05);不良反应发生率两组无明显差异(P>0.05)。[结论]对高龄晚期食管鳞癌患者应用替吉奥同期调强放疗治疗,近期疗效好,不良反应未增加,值得临床推广。
[Objective] To explore the short-term curative effect and safety of Tianguo radiotherapy for advanced esophageal squamous cell carcinoma in the same period. [Methods] One hundred elderly advanced esophageal squamous cell carcinoma patients were randomly divided into two groups (n = 50 in each group). All patients were treated with full-intensity intensity modulated radiation therapy (IMRT). On the basis of this study, After oral administration of TEGO capsule, the two groups of patients were observed for the short-term curative effect after three cycles of chemotherapy. At the same time, the 1-year survival rate, local control rate, survival time and the incidence of adverse reactions were recorded. [Results] After treatment, the effective rate of the treatment group was 84.00% and the effective rate of the control group was only 62.00%. The short-term curative effect of the treatment group was better than that of the control group (P <0.05) After treatment, the 1-year survival rate, local control rate and mean survival time in the two groups were significantly higher than those in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). [Conclusion] The application of GGT for the treatment of advanced esophageal squamous cell carcinoma in elderly patients with esophageal squamous cell carcinoma in the recent period has good curative effect and no adverse reactions, which is worthy of clinical promotion.